Foundation awards $21M in grants for multicenter myeloma research
Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly…
Margarida Maia, PhD, science writer—
Articles by Margarida Maia
Aphexda approved in US to improve autologous stem cell transplants
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT)…
Some myeloma cells may mutate to resist T-cell therapies: Study
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of T-cell therapies, according to a…
Positive early results seen for CAR T-cell therapy for myeloma in trial
Most patients with hard-to-treat multiple myeloma given NXC-201 — Nexcella’s experimental point-of-care CAR T-cell therapy — as part of a clinical trial in…
SP-3164 ‘Molecular Glue’ Stops Growth In Lab-grown Cells, Mice
SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from…
Pepaxti Approved to Treat Resistant Multiple Myeloma in Europe
The European Commission has approved Pepaxti (melphalan flufenamide, also called melflufen), a medicine by Oncopeptides to be used in combination with dexamethasone, making it…
Pepaxti Combo Favored to Treat Advanced Multiple Myeloma in EU
Oncopeptides received a positive opinion from an arm of the European Medicines Agency (EMA) that is expected to take the company one step closer…
